Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1
Hepatology2017Vol. 66(6), pp. 1920–1933
Citations Over TimeTop 10% of 2017 papers
Abstract
Targeting mammalian target of rapamycin pathways in combination with PD-1 may result in increased antitumor efficacy in cancer patients. (Hepatology 2017;66:1920-1933).
Related Papers
- → Mechanisms of Resistance to PD-1 and PD-L1 Blockade(2018)396 cited
- → Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer(2016)34 cited
- → A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade(2023)4 cited
- → γδ T cells as unconventional targets of checkpoint blockade(2024)1 cited
- → Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer(2014)